Definium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of ...

Lily A. Brown, PhD, describes a patient with generalized anxiety disorder (GAD) who sought urgent consultation despite prior evaluations by multiple clinicians internationally. The patient’s continued ...

Earlier this month, Definium Therapeutics reported results from a large U.S. healthcare claims study of more than 1.27 ...

Dr Bradley N. Gaynes reflects on how the understanding and treatment of generalized anxiety disorder (GAD) has evolved over the past three decades. One major advance has been the improved ability to ...

Individuals with generalized anxiety disorder (GAD), a condition characterized by daily excessive worry lasting at least six months, have a high relapse rate even after receiving treatment. Artificial ...

Ashwini Nadkarni, MD, of Mass General Brigham, discusses what’s new in the management of generalized anxiety disorder.

In the mental health field, we tend to pathologize and diagnose even commonly encountered challenges. Through the lens of human experience, however, we can recognize that some emotional and mental ...

In a world of constant connectivity and mounting pressures, generalized anxiety disorder (GAD) has emerged as a significant mental health challenge affecting millions. Recent studies show that anxiety ...

There is no best medication for generalized anxiety disorder (GAD). Doctors base treatment plans on factors such as the severity of symptoms and the person’s response to the recommended drugs. However ...